Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meclizine is a piperazine-derivative antihistamine classified as an anticholinergic antiemetic. It is primarily used to prevent and treat nausea, vomiting, and dizziness associated with motion sickness and to manage vertigo caused by diseases affecting the vestibular system. Meclizine acts as a histamine H1 receptor antagonist with additional anticholinergic and central nervous system depressant properties. Its mechanism of action involves depressing labyrinth excitability and conduction in vestibular-cerebellar pathways[5][7]. The drug is available in oral tablet forms (including chewable) for adults and children aged 12 years or older[3]. Developed by Pfizer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meclizine.